Dermapharm Holding SEFRA:DMP 87 EBITDA Margin % is 30.27% as of Mar. 2026, which is 24% above its 10-year median of 24.43. GuruFocus rates FRA:DMP with a GF Score™ of 87/100 and a GF Value™ of €39.11 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 955 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 84.4% on this metric.
Dermapharm Holding SE (FRA:DMP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dermapharm Holding SE EBITDA Margin % Related Terms
Dermapharm Holding SE EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DMP vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (FRA:DMP) has a EBITDA Margin % of 30.27% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dermapharm Holding SE and its competitors. This is 24% above median its historical median of 24.43. Over the past decade, Dermapharm Holding SE's EBITDA Margin % has ranged from 23.15 to 37.90. According to the industry distribution chart, Dermapharm Holding SE ranks #149 out of 955 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Dermapharm Holding SE's EBITDA Margin % too high?
Dermapharm Holding SE's current EBITDA Margin % of 30.27% is 24% above median its 10-year median of 24.43. Over the past 10 years, this metric has ranged from a low of 23.15 to a high of 37.90. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Dermapharm Holding SE's value of 30.27% is 143.3% above this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #149 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dermapharm Holding SE has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #149 out of 955 companies for EBITDA Margin %. This places Dermapharm Holding SE in the top 16% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Dermapharm Holding SE's value of 30.27% is 143.3% above this benchmark. Historically, Dermapharm Holding SE's own EBITDA Margin % has ranged from 23.15 to 37.90 over the past decade. While the company's 10-year median is 24.43 vs. the industry median of 12.44, Dermapharm Holding SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current EBITDA Margin % of 30.27% is 143.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current EBITDA Margin % is 30.27%, which is 24% above median its own 10-year median of 24.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (FRA:DMP) is currently considered Modestly Overvalued. The stock's GF Value™ is €39.11, compared to a current price of €46.25 — trading 18.3% above its estimated fair value. The current EBITDA Margin % is 30.27%, which is 24% above median its 10-year median of 24.43 and 143.3% above the Drug Manufacturers industry median of 12.44. Dermapharm Holding SE's overall GF Score™ is 87/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dermapharm Holding SE (FRA:DMP), the current EBITDA Margin % is 30.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (FRA:DMP) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.25 is trading 18.3% above its estimated GF Value™ of €39.11.
GuruFocus considers Dermapharm Holding SE to be Modestly Overvalued.
Key valuation signals for FRA:DMP:
EBITDA Margin %: 30.27% (24% above median its 10-year median of 24.43)
GF Value™: €39.11 vs. price of €46.25 (18.3% above fair value)
Industry Position: 143.3% above the Drug Manufacturers median (#149 of 955)
No single metric tells the full story. See the FRA:DMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
87GF Score
Get the complete analysis for FRA:DMP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMP has been successfully added to your 
